Trial Profile
Phase II Study of ARQ 197 Monotherapy for Previously Treated Advanced/Recurrent Gastric Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2019
Price :
$35
*
At a glance
- Drugs Tivantinib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 17 May 2012 Resutls will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to an ArQule and Daiichi Sankyo media release.
- 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.